Fordelene ved bivalirudin overfor UFH/ enoxaparin plus GPIIb/ IIIa- inhibitor i forhold til tilfælde af blødninger er kun overvåget i bivalirudin- monotarapiarmen.
The advantage of bivalirudin over UFH/ enoxaparin plus GPIIb/ IIIa inhibitor in terms of bleeding events was only observed in the bivalirudin monotherapy arm.